Sugi Predict

Sugi Predict / Compounds / SCHEMBL3578249

SCHEMBL3578249

SCHEMBL3578249

CC(C)(C)c1cc(C#N)cc(C(C)(C)C)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.56
▸ CA1 P00915 2/20 0.56
▸ SMN1; SMN2 Q16637 6/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ POLB P06746 1/20 0.54
▸ TYR P14679 1/20 0.54
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ MAPT P10636 4/20 0.53
▸ TSHR P16473 4/20 0.53
▸ GAA P10253 4/20 0.53
▸ ALOX15 P16050 3/20 0.53
▸ CYP3A4 P08684 3/20 0.53
▸ BLM P54132 3/20 0.53
▸ HSD17B10 Q99714 3/20 0.53
▸ LMNA P02545 3/20 0.53
▸ CYP1A2 P05177 3/20 0.53
▸ CYP2C9 P11712 3/20 0.53
▸ CYP2C19 P33261 3/20 0.53
▸ RGS12 O14924 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6748702 0.90 TTR (0.47) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL10765819 0.86 TTR (0.70) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL10766961 0.86 MEN1 (0.64) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL6888576 0.83 MEN1 (0.50) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL2154631 0.81 KIF11 (0.40) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL29022938 0.81 CA2 (0.61) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL2153658 0.79 KIF11 (0.39) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL26259851 0.79 KIF11 (0.39) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL29437966 0.78 ALDH1A1 (0.57) CA2SMN1; SMN2ALDH1A1POLBTYR
SCHEMBL5368308 0.78 ALDH1A1 (0.57) CA2SMN1; SMN2ALDH1A1POLBTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119708713-A Surface superhydrophobic vulcanized rubber and preparation method thereof 南通睿沣新材料技术有限公司 2025-03-28 — — CN claimed
CN-119060417-A Starch-based degradable composite material and preparation method thereof 台州黄岩泽钰新材料科技有限公司 2024-12-03 — — CN claimed
US-20240325340-A1 ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE LANDAUER, STEPHEN PAUL 2024-10-03 — — US claimed
WO-2023009629-A1 ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE THOMAS JEFFERSON UNIVERSITY (US) 2023-02-02 — — WO claimed
CN-119708713-A Surface superhydrophobic vulcanized rubber and preparation method thereof 南通睿沣新材料技术有限公司 2025-03-28 — — CN disclosed
CN-119060417-A Starch-based degradable composite material and preparation method thereof 台州黄岩泽钰新材料科技有限公司 2024-12-03 — — CN disclosed
US-20240325340-A1 ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE LANDAUER, STEPHEN PAUL 2024-10-03 — — US disclosed
WO-2023009629-A1 ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE THOMAS JEFFERSON UNIVERSITY (US) 2023-02-02 — — WO disclosed
WO-2019163638-A1 ACTIVE ENERGY RAY CURABLE RESIN COMPOSITION, ANTIFOGGING ANTIFOULING LAMINATE, AND MANUFACTURING METHOD, ARTICLE, AND ANTIFOGGING METHOD THEREOF デクセリアルズ株式会社 2019-08-29 — — WO disclosed
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2010-11-11 — — US disclosed
EP-1270577-B1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-12-06 — — EP disclosed
US-6924292-B2 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 — — US disclosed
EP-0371438-B1 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents WARNER LAMBERT CO (US) 1995-08-30 — — EP disclosed
EP-0371438-A2 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents WARNER-LAMBERT COMPANY (US) 1990-06-06 — — EP disclosed
US-4207229-A STABILIZING POLYPROPYLENE AGAINST THERNAL, OXIDATIVE AND ULTRAVIOLET LIGHT DEGRADATION CIBA-GEIGY CORPORATION (US) 1980-06-10 — — US disclosed
US-4195016-A STABILIZERS OF POLYMERS AGAINST THERMAL, OXIDATIVE, AND ULTRAVIOLET LIGHT DEGRADATION CIBA-GEIGY CORPORATION (US) 1980-03-25 — — US disclosed
US-4182704-A STABILIZERS CIBA-GEIGY CORPORATION (US) 1980-01-08 — — US disclosed
US-4180497-A STABILIZERS FOR ORGANIC POLYMERS AGAINST THERMAL, OXIDATIVE AND UV LIGHT DEGRADATION CIBA-GEIGY CORPORATION (US) 1979-12-25 — — US disclosed
US-4180498-A STABILIZERS OF POLYMERS AGAINST THERMAL, OXIDATIVE, AND ULTRAVIOLET LIGHT DEGRADATION CIBA-GEIGY CORPORATION (US) 1979-12-25 — — US disclosed
US-4094855-A Hindered phenyl phosphites CIBA-GEIGY CORPORATION (US) 1978-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240325340-A1 ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE AKT3, AKT1, AKT2 CA2 4052/4885CA1 4688/4885SMN1; SMN2 1012/4885
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators CXCR3, CXCR1, CXCR2 CA2 1889/4885CA1 3314/4885SMN1; SMN2 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.